COVID-19 Vaccine Volunteer in Brazil’s AstraZeneca Trial Dies

COVID-19 Vaccine Volunteer in Brazil’s AstraZeneca Trial Dies

In Brazil a volunteer who had undergone vaccine anti-covid testing died.

The news was released by Anvisa, the National Health Supervisory Agency. Despite the man’s death, Anvisa has communicated that the experiments will not stop and indeed, the collaborator of the University of Oxford Piero di Lorenzo he announced that the trial could be completed by the end of November or at the latest in early December.

In fact, according to what is reported by Anvisa, there would have been no concerns “about the safety of the clinical trial”.

A volunteer who was taking part in the AstraZeneca vaccine trial program in collaboration with the University of Oxford he passed away. The news was revealed by the National Health Supervisory Agency (Anvisa). However, this is an event that may not lead to a suspension of the experiments currently underway.

In this regard, Piero di Lorenzo, a collaborator of the University of Oxford for the AstraZeneca vaccine experimentation declared in an interview with the magazine Finacial Lounge: “If no sudden problems arise, it is reasonable to think that the clinical trial phase can be completed by the end of November. or early December “.

Di Lorenzo then went on to state that once the third phase is concluded, the trials will be passed to the European Medicines Agency (Ema) who will have the task of proceeding with a possible validation of the vaccine. “Once phase 3 is over, the ball passes to the EMA for possible validation”, he declared. He then specified that if in normal times it takes about 12 months, given the exceptional times the times could be shortened a lot.

In addition to this according to what is reported by the Brazilian newspaper O Globo, the volunteer would die because he was not given the test vaccine dose, but a placebo. Following the spread of the news, the shares of AstraZeneca fell on the stock market with a decrease of 1.7%

COMMENTS

WORDPRESS: 0
DISQUS: 0